Based on her unique experiences and biological needs, each woman has her definition of what is a “normal period.” However, a condition known as hypoactive sexual desire disorder (HSDD) may be present in a woman with low sexual desire or low libido and is troubled by this lack of interest in sex.
A woman’s libido can fluctuate from time to time. Stress, hormonal changes, and drug side effects can all reduce sex desire. However, these times are typically brief, and desire quickly returns.
According to the Society for Women’s Health Research, HSDD is one of the most prevalent female sexual health problems, affecting one in ten women. A lack of sexual fantasies and the urge to engage in sexual activity results in significant distress or interpersonal trouble; it is the key component of female HSDD. Fortunately, there are medications for it, such as Addyi. Read on to learn more.
What Exactly Is Addyi?
In premenopausal women with HSDD, Addyi is a prescription drug that increases sexual desire while reducing emotional distress. It should only be taken when a lack of sex isn’t brought on by a physical ailment, mental illness, marital issues, drug usage, or other medications.
Although Addyi is usually referred to as the female version of Viagra, it works substantially differently. While Addyi may function more like an antidepressant by reversing an imbalance of neurotransmitters in the brain that leads to sexual cravings, Viagra works by increasing blood flow to the genitals.
The brain’s levels of dopamine, serotonin, and norepinephrine are impacted. Addyi is taken every day at bedtime and is available as a tablet. Drinking is not advised while using this medication. You shouldn’t use Addyi if you have liver problems or recently drank alcohol.
Some medications can have adverse or severe effects when taken with Addyi. Your doctor might modify your treatment regimen if you use:
- Antifungal medication such as fluconazole, itraconazole, ketoconazole, or posaconazole;
- Antibiotics such as clarithromycin, ciprofloxacin, telithromycin, or erythromycin;
- Antiviral medication to treat hepatitis C, such as boceprevir, or an HIV or AIDS medication, such as atazanavir, fosamprenavir, indinavir,
Inform your doctor of any of the following to ensure that Addyi is safe for you:
- Addiction to drugs, depression or other mental illnesses, low blood pressure, alcoholism (or if you currently drink alcohol), or any of these.
- There isn’t enough research available just yet to prove that this medication will not harm an unborn child. Therefore, if you are pregnant or want to become pregnant, let your doctor know.
- Using this medication while nursing is not advised.
- Anyone under the age of 18 is not allowed to use flibanserin.
Here’s how to use Addyi
- Take Addyi as directed by your physician. Read all drug guides or instruction sheets and adhere to all instructions on your prescription label.
- Before taking Addyi and until the following day, refrain from drinking alcohol for at least two hours. If you use flibanserin and alcohol, your blood pressure could dangerously drop. If you drank alcohol less than two hours ago, skip your bedtime dose.
- You may feel lightheaded if you take flibanserin, which lowers blood pressure. If you are not already in bed, lie down if you have dizziness after taking this medication.
- Store your medication at room temperature, away from heat and moisture.
5 Things to Know About Addyi
1. Addyi And Vyleesi Subsets Of Women
Drugs like Addyi (flibanserin) and Vyleesi (bremelanotide) are used to treat premenopausal women with hypoactive sexual desire disorder (HSDD). Vyleesi is an injectable that the patient administers on their own as needed, and Addyi is an oral pill that the patient takes once daily at bedtime.
Addyi – In clinical trials, around 10% more individuals receiving Addyi than placebo reported appreciable improvements in gratifying sexual events, sexual desire, or sexual distress.
Vyleesi – During clinical trials, around 25% of women receiving Vyleesi experienced a boost in their sexual desire score, compared to approximately 17% of women receiving a placebo.
2. Flibanserin Is Indicated To Treat Hypoactive Sexual Desire Disorder
The first drug to treat acquired, global hypoactive sexual desire disorder (HSDD) in premenopausal women is Flibanserin, which the FDA approved in August 2015. Only marginal improvements in the signs and symptoms of decreased sexual desire have been seen in clinical trials with the drug (number of sexual desire, satisfying sexual events [SSEs], and overall sexual function).
3. Flibanserin Is A Multifunctional Serotonin
A new multifunctional serotonin agonist and antagonist (MSAA) called flibanserin enhances sexual performance in premenopausal women who have decreased sexual interest and desire.
Synaptic dopamine and other microcircuits where norepinephrine, testosterone, and estrogen function positively influence libido. Microcircuits where prolactin and serotonin act negatively affect libido.
It means that sexual interest and desire dysfunction can result from either a relative excess of microcircuit serotonin or a relative shortage of dopamine and norepinephrine.
Flibanserin works as a complete agonist towards postsynaptic 5HT1A receptors and an antagonist towards postsynaptic 5HT2A receptors in neuronal microcircuits, respectively.
4. Hormonal Contraceptives May Cause Additional Side Effects
The only information that is now available indicates that using hormonal birth control while taking Addyi increases the risk of significant problems. Addyi is only licensed for premenopausal women who are most likely to use hormonal birth control.
Women who took hormonal contraceptives experienced several side effects, such as drowsiness, lightheadedness, and weariness, more frequently. The recognized impact of hormonal contraceptives on CYP3A4 may result in a 40% increase in Addyi exposure.
5. Addyi Can Depress The Central Nervous System
Syncope, central nervous system depression, dizziness, sleepiness, weariness, nausea, sedated condition, and hypotension are only a few of the side effects of Addyi that are frequently reported. Among the other adverse effects is sleeplessness.
The central nervous system depressant (CNS depressant) effects of amoxapine may be exacerbated by flibanserin.
Addyi is the #1 prescribed treatment for HSDD in women who have not experienced menopause, who have not previously experienced issues with low sexual desire, and who have low sexual desire regardless of the sexual activity, the circumstance, or the partner.
For the treatment of HSDD in menopausal women, men, or children, Addyi is not recommended. The purpose of Addyi is not to improve sexual performance.